Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer.

ABSTRACT:

Aim

The use of bevacizumab in combination therapy is an emerging trend in metastatic colorectal cancer treatment. However, the clinical value of different combination types remains under debate. Thus, a meta-analysis of randomized controlled trials (RCTs) comparing bevacizumab-based combination therapy with monotherapy (therapy that uses one type of treatment, such as chemotherapy or surgery alone, to treat metastatic colorectal cancer) was performed, aiming to evaluate the safety and efficacy of bevacizumab-based combination therapy and to find a more beneficial combination.

Methods

We searched for clinical studies that evaluated bevacizumab-based combination therapy in metastatic colorectal cancer. We extracted data from these studies to evaluate the relative risk (RR) of

SUBMITTER: Xu R 

PROVIDER: S-EPMC6287670 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature